Zydus Lifesciences shares rise 5% on deal with US healthcare firm CVS Caremark

Zydus Lifesciences shares rise 5% on deal with US healthcare firm CVS Caremark

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Zydus Lifesciences share price advanced over 5 percent in trade today after the company announced an agreement with US healthcare firm CVS Caremark to add its diabetes combination products to its template formulary.

The company in an exchange filing on January 7 said, Zituvio and combination products include ZituvioTM (sitagliptin), ZituvimetTM (sitagliptin and metformin hydrochloride) and ZituvimetTM XR (sitagliptin and metformin hydrochloride) extended-release tablets. These three NDAs of Sitagliptin (base) and combination franchise have been approved by the USFDA earlier through the 505(b)(2) route."

"The Zituvio range of products contain active ingredients sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and metformin hydrochloride (HCl), a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus," the company said.

Zydus Lifesciences reacted sharply to the development in Tuesday's trade with the counter rising 5.23 percent to an intraday high of Rs 1,011.75 per share on the NSE.

Punit Patel, President & CEO Zydus Pharmaceuticals USA Inc., commented on the development, saying, "We are proud to have partnered with CVS Caremark, one of the most patient-centric healthcare solutions providers in the US, to further our commitment to improving access to high-quality medications to patients and meeting their healthcare needs with reduced outlays."

The shares of the company have delivered 40.70 percent returns in the last one year, according to the data available on the BSE.

Disclaimer: The views and investment tips expressed by experts on Moneycontrol are their own and not those of the website or its management. Moneycontrol advises users to check with certified experts before taking any investment decisions.